Martin Zweifel1, Daniel Patterson1, N J. Taylor2, J J. Stirling2, David J. Collins3, James A. d'Arcy3, Martin O. Leach3, Gordon J. Rustin1, Anwar R. Padhani2
1Medical Oncology, Mount Vernon Hospital, Northwood, Middlesex HA6 2RN, United Kingdom; 2Paul Strickland Scanner Centre, Mount Vernon Hospital, Northwood, Middlesex HA6 2RN, United Kingdom; 3CRUK-EPSRC Cancer Imaging Centre, Institute of Cancer Research & Royal Marsden Hospital, Sutton, Surrey, SM2 5PT, United Kingdom
This is a report of the first, in man study of serial BOLD MRI after a vascular disruptive agent in a translational phase I clinical trial of OXi4503. Changes observed in R2* were used to define onset of VDA activity and results are compared to DCE-MRI changes at 4 hours. R2*showed significant VDA within the 1st few hours. Both R2*and DCE-MRI show positive dose-response relationships. If both R2*and DCE-MRI parameters are used to assess OXI4503 activity (by significant increases in R2*and decreases in Ktrans/IAUGC60), then 52% of lesions show MRI changes consistent with VDA effect.